Final Judgment Entered in Kurin’s Favor over Magnolia Medical

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court for the District of Delaware entered Final Judgment that Kurin does not infringe Magnolia Medical, Inc.’s patent. The district court proceedings in the patent infringement lawsuit brought by Magnolia in 2019 are now closed.

“We are pleased that the Court has ruled in our favor,” said Bob Rogers, CEO of Kurin, Inc. “This case took five years and during that time Magnolia has loudly proclaimed that they would put Kurin out of business, creating confusion in the marketplace. We took the high road with our customers and, although it took years, we stayed true to our values and prevailed in the end.”

“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of the key patent claims that were the cornerstone of this litigation. This is a complete victory for our team, confirming both that the Kurin Lock does not infringe any Magnolia patent and that the asserted patent is invalid. We are pleased to have this distraction behind us and can now continue on our mission of partnering with clinicians to improve clinical and financial outcomes regarding blood culture contaminations.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.